Off‐label prescriptions of drugs used for the treatment of Crohn’s disease or ulcerative colitis

BACKGROUND: Off‐label prescribing is encountered across various fields of medicine and creates alternative treatment options, but is associated with unknown safety risks. The use of off‐label drugs for the treatment of patients with inflammatory bowel diseases (IBD) has not been characterised before...

Descripción completa

Detalles Bibliográficos
Autores principales: Simsek, Melek, Lissenberg‐Witte, Birgit I., van Riswijk, Milou L. M., Verschuren, Sander, Hoentjen, Frank, Oldenburg, Bas, Ponsioen, Cyriel Y., van der Woude, C. Janneke, van der Meulen, Andrea E., Pierik, Marieke, Dijkstra, Gerard, de Boer, Nanne K. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Off‐label Drug Prescribing in Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593662/
https://www.ncbi.nlm.nih.gov/pubmed/30908719
http://dx.doi.org/10.1111/apt.15229

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593662/
https://www.ncbi.nlm.nih.gov/pubmed/30908719
http://dx.doi.org/10.1111/apt.15229

Ejemplares similares